Test for First-Episode Psychosis (FEP) prognosis
Currently, only 25% of patients treated with antipsychotic drugs show a complete response to treatment. The scientific and medical community is highlighting the need of finding biomarkers liable to predict, at early stages of the disease, the response to treatment.
Our technology aims to provide an accurate tool to determine the best pharmaceutical treatment for each FEP patient. It is based in the determination of the expression of some receptors in peripheral blood samples.
The advantages of this new test are:
Non invasive, standardized technique
Predicts the response to FEP treatment
Useful as companion diagnostic
Estado de protección
A Spanish priority patent application was filed in June 2015 at the Spanish Patent Office (P201530918). An international PCT application has been filed on June 2016.
Cooperación que se desea
CIBER is seeking an industrial partner for licensing out and to further develop this technology.
- Tecnología sanitaria:
- Biotecnología y Diagnóstico Molecular (proteómica, genómica, etc...)